IPHA Stock Overview
Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 6/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for IPHA from our risk checks.
Innate Pharma S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €2.46 |
52 Week High | €3.57 |
52 Week Low | €1.81 |
Beta | 0.67 |
1 Month Change | -14.58% |
3 Month Change | -9.23% |
1 Year Change | -16.61% |
3 Year Change | -41.98% |
5 Year Change | n/a |
Change since IPO | -59.93% |
Recent News & Updates
Recent updates
Innate Pharma: Worth A Deeper Look
Jan 11Innate Pharma GAAP EPS of €0.08, revenue of €45.59M
Sep 15Innate stock rises as Sanofi progress on 2nd cancer drug compound, pay €3M
Jul 21Innate Pharma: Leading The NK Cell Immunotherapy Space
Oct 06Innate Pharma: Attractive Price, But Comes With Uncertainty
Jan 29Innate Pharma files $200M equity shelf
Jan 13Innate Pharma gives back US, EU Lumoxiti rights to AZN
Dec 11Innate Pharma reports 9M results
Nov 17EMA grants PRIME tag to Innate Pharma's lacutamab for T-cell lymphoma
Nov 13Shareholder Returns
IPHA | US Biotechs | US Market | |
---|---|---|---|
7D | 0.8% | -0.2% | 2.9% |
1Y | -16.6% | -1.0% | 22.2% |
Return vs Industry: IPHA underperformed the US Biotechs industry which returned -1% over the past year.
Return vs Market: IPHA underperformed the US Market which returned 22.2% over the past year.
Price Volatility
IPHA volatility | |
---|---|
IPHA Average Weekly Movement | 9.9% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IPHA has not had significant price volatility in the past 3 months.
Volatility Over Time: IPHA's weekly volatility (10%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 179 | Herve Brailly | www.innate-pharma.com |
Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET.
Innate Pharma S.A. Fundamentals Summary
IPHA fundamental statistics | |
---|---|
Market cap | US$194.15m |
Earnings (TTM) | -US$8.10m |
Revenue (TTM) | US$65.94m |
2.9x
P/S Ratio-24.0x
P/E RatioIs IPHA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IPHA income statement (TTM) | |
---|---|
Revenue | €61.64m |
Cost of Revenue | €56.02m |
Gross Profit | €5.62m |
Other Expenses | €13.19m |
Earnings | -€7.57m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 12, 2024
Earnings per share (EPS) | -0.094 |
Gross Margin | 9.12% |
Net Profit Margin | -12.28% |
Debt/Equity Ratio | 75.3% |
How did IPHA perform over the long term?
See historical performance and comparison